Advertisement

Pathophysiology: Gut Liver Axis Changes

  • Charlotte Woodhouse
  • Debbie Shawcross
Chapter

Abstract

The liver is at the intersection between the gut and the systemic circulation. Consequently it is the first recipient of the by-products of digestion including nitrogenous waste and thus the factory for processing and detoxifying these compounds. In cirrhosis, this detoxification capacity is overwhelmed by a combination of impaired urea synthesis and bypassing of blood rich in ammonia directly into the systemic circulation as a result of portal hypertension. This chapter describes the pathogenesis of hepatic encephalopathy (HE) and the complex relationship between the liver and gut. The changes in gut microbiota that occur in cirrhosis and the various strategies of manipulating the gut flora to treat and prevent HE are discussed utilising an evolving typical clinical case scenario.

Keywords

Ammonia Infection Microbiome Antibiotic Probiotic Prebiotic 

References

  1. 1.
    Floch MH, Katz J, Conn HO. Qualitative and quantitative relationships of the fecal flora in cirrhotic patients with portal systemic encephalopathy and following portacaval anastomosis. Gastroenterology. 1970;59(1):70–5.PubMedGoogle Scholar
  2. 2.
    Weber FL Jr, Veach GL. The importance of the small intestine in gut ammonium production in the fasting dog. Gastroenterology. 1979;77(2):235–40.PubMedGoogle Scholar
  3. 3.
    Weber FL, Friedman DW, Fresard KM. Ammonia production from intraluminal amino acids in canine jejunum. Am J Physiol. 1988;254(2 Pt 1):G264–8.PubMedGoogle Scholar
  4. 4.
    Nance FC, Kaufman HJ, Kline DG. Role of urea in the hyperammonaemia of germ free Eck fistula dogs. Gastroenterology. 1974;66:108–12.PubMedGoogle Scholar
  5. 5.
    Kline DG, Nance FC. Eck’s fistula encephalopathy in germ free dogs. Ann Surg. 1971;174(5):856–62.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Schalm SW, van der Mey T. Hyperammonemic coma after hepatectomy in germ-free rats. Gastroenterology. 1979;77:231–4.PubMedGoogle Scholar
  7. 7.
    Romero-Gomez M, Ramos-Guerrero R, Grande L, de Teran LC, Corpas R, Camacho I, et al. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol. 2004;41(1):49–54.CrossRefPubMedGoogle Scholar
  8. 8.
    Patel VC, White H, Stoy S, Bajaj JS, Shawcross DL. Clinical science workshop: targeting the gut-liver-brain axis. Metab Brain Dis. 2016;31(6):1327–37.CrossRefPubMedGoogle Scholar
  9. 9.
    Cordoba J, Alonso J, Rovira A, Jacas C, Sanpedro F, Castells L, Vargas V, Margarit C, Kulisewsky J, Esteban R, Guardia J. The development of low-grade cerebral edema in cirrhosis is supported by the evolution of 1H-magnetic resonance abnormalities after liver transplantation. J Hepatol. 2001;35:598–604.CrossRefPubMedGoogle Scholar
  10. 10.
    Bessman AN, Hawkins R. The relative effects of enterically administered plasma and packed cells on circulating blood ammonia. J Biol Chem. 1962;237:3151–6.Google Scholar
  11. 11.
    Jalan R, Olde Damink SWM, Lui HF, Glabus M, Deutz NEP, Hayes PC, Ebmeier K. Oral amino acid load mimicking hemoglobin results in reduced regional cerebral perfusion and deterioration in memory tests in patients with cirrhosis of the liver. Metab Brain Dis. 2003;18(1):37–49.CrossRefPubMedGoogle Scholar
  12. 12.
    Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, Auzinger G, Bernal W, Wendon JA. Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol. 2011;54:640–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Aldridge DR, Tranah EJ, Shawcross DL. Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. J Clin Exp Hepatol. 2015;5(Suppl 1):S7–S20.CrossRefPubMedGoogle Scholar
  14. 14.
    Shawcross DL, Wright G, Olde Damink SW, Jalan R. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis. 2007;22(1):125–38.CrossRefPubMedGoogle Scholar
  15. 15.
    Jalan R, Kapoor D. Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver. Gut. 2003;52(7):1041–5.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Conn HO, Lieberthal MM. The hepatic coma syndromes and lactulose. Baltimore: Williams and Wilkins; 1979.Google Scholar
  17. 17.
    Quigley EM, Stanton C, Murphy EF. The gut microbiota and the liver. Pathophysiologcal and clinical implications. J Hepatol. 2013;58:1020–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Singh R, Bullard J, Kalra M, Assefa S, Kaul AK, Vonfeldt K, et al. Status of bacterial colonization, Toll-like receptor expression and nuclear factor-kappa B activation in normal and diseased human livers. Clin Immunol. 2011;138(1):41–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Scott KP, Gratz SW, Sheridan PO, Flint HJ, Duncan SH. The influence of diet on the gut microbiota. Pharmacol Res. 2013;69(1):52–60.CrossRefGoogle Scholar
  20. 20.
    Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54(2):562–72.CrossRefGoogle Scholar
  21. 21.
    Bajaj JS, Heuman DM, Hylemin PB, Sanyal AJ, White MB. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60:940–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology. 2004;39(5):1441–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2012;302(1):G168–75.CrossRefPubMedGoogle Scholar
  24. 24.
    Cordoba J, Lopez-Hellin J, Planas M, Sabin P, Sanpedro F, Castro F, Esteban R, Guardia J. Normal protein diet for episodic HE: results of a randomised study. J Hepatol. 2004;41:38–43.CrossRefPubMedGoogle Scholar
  25. 25.
    Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328(7447):1046.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;4:CD003044.PubMedGoogle Scholar
  27. 27.
    Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–81.CrossRefGoogle Scholar
  28. 28.
    Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2014;12(8):1390–7.e2.CrossRefPubMedGoogle Scholar
  29. 29.
    Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther. 2016;43(Suppl 1):11–26.CrossRefPubMedGoogle Scholar
  30. 30.
    Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013;8(4):e60042.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Zhao LN, Yu T, Lan SY, Hou JT, Zhang ZZ, Wang SS, et al. Probiotics can improve the clinical outcomes of hepatic encephalopathy: an update meta-analysis. Clin Res Hepatol Gastroenterol. 2015;39(6):674–82.CrossRefPubMedGoogle Scholar
  32. 32.
    Saab S, Suraweera D, Au J, Saab EG, Alper TS, Tong MJ. Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials. Liver Int. 2016;36(7):986–93.CrossRefPubMedGoogle Scholar
  33. 33.
    Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology. 2017;66:1727–38.CrossRefPubMedGoogle Scholar
  34. 34.
    Kao D, Roach B, Park H, Hotte N, Madsen K, Bain V, et al. Fecal microbiota transplantation in the management of hepatic encephalopathy. Hepatology. 2016;63(1):339–40.CrossRefPubMedGoogle Scholar
  35. 35.
    Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010;51(5):1675–82.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Liver Sciences, 1st Floor JBC, School of Immunology and Microbial SciencesFaculty of Life Sciences and Medicine, King’s College London, Denmark Hill CampusLondonUK

Personalised recommendations